Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
Adaptive Biotechnologies Corp
Last earnings -5.0% on 2026-05-05
Revenue grew 54.8% YoY; but unprofitable (net margin -21.5%).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
Adaptive Biotechnologies Corp shows $277M in FY2025 revenue (+54.8% YoY), a -21.5% net margin, and -27.2% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro$19/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001478320, latest 10-Q filed 2026-05-05) · EODHD · rules-based read · as of 6/18/2026, 7:06:06 AM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $154M | $185M | $170M | $179M | $277M |
| Gross profit | — | — | — | — | — |
| Operating income | -$209M | -$200M | -$227M | -$163M | -$57.1M |
| Net income | -$207M | -$200M | -$225M | -$159M | -$59.5M |
| Diluted EPS | -$1.48 | -$1.40 | -$1.56 | -$1.08 | -$0.39 |
| Net margin | -134.3% | -108.0% | -132.3% | -89.1% | -21.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median
Last 90 days: 0 open-market buys · 13 sales
| 2026-06-16 | ROBINS HARLAN S Chief Scientific Officer | Sell | 6.16K @ $18.01 | $111K |
| 2026-06-15 | ROBINS HARLAN S Chief Scientific Officer | Sell | 100K @ $17.37 | $1.74M |
| 2026-06-11 | BOBULSKY SUSAN Chief Commercial Officer, MRD | Sell | 5.00K @ $19.00 | $95.0K |
| 2026-06-04 | LO FRANCIS Chief People Officer | Exercise | 5.79K @ $12.14 | $70.3K |
| 2026-06-04 | LO FRANCIS Chief People Officer | Exercise | 2.01K @ $8.46 | $17.0K |
| 2026-06-04 | LO FRANCIS Chief People Officer | Exercise | 2.34K @ $3.99 | $9.35K |
| 2026-06-04 | LO FRANCIS Chief People Officer | Exercise | 9.38K @ $8.12 | $76.1K |
| 2026-06-04 | LO FRANCIS Chief People Officer | Sell | 39.7K @ $17.49 | $695K |
| 2026-06-04 | BOBULSKY SUSAN Chief Commercial Officer, MRD | Sell | 11.0K @ $18.00 | $198K |
| 2026-05-18 | PISKEL KYLE Chief Financial Officer | Sell | 3.12K @ $13.04 | $40.6K |
| 2026-04-27 | RUBINSTEIN JULIE President and COO | Exercise | 14.7K @ $8.46 | $124K |
| 2026-04-27 | RUBINSTEIN JULIE President and COO | Sell | 19.0K @ $14.23 | $271K |